Brainstorm Cell Therapeutics Inc (NAS:BCLI)
$ 2.35 0.12 (5.38%) Market Cap: 12.72 Mil Enterprise Value: 13.39 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Q4 2020 Brainstorm Cell Therapeutics Inc Earnings Call Transcript

Feb 04, 2021 / 01:00PM GMT
Release Date Price: $118.2 (+27.71%)
Operator

Greetings and welcome to the BrainStorm Cell Therapeutics' fiscal year-end 2020 earnings call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to introduce your host, Mr. Michael Wood of LifeSci Advisors. Mr. Wood, you may begin.

Michael Wood
LifeSci Advisors, LLC - IR

Thank you, and good morning, everyone. Thank you for joining the BrainStorm Cell Therapeutics call. Before we begin the opening remarks, we'd like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding BrainStorm Cell Therapeutics and its potential future business operations and performance.

Statements regarding the market potential for the treatment of neurodegenerative disorders such as ALS and MS, sufficiency of the company's existing capital resources for continuing operations in 2021 and beyond, the [findings to date] regarding the tolerability and full potential of the NurOwn technology platform, clinical trials of NurOwn and related clinical development

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot